scispace - formally typeset
Y

Yunlong Liu

Researcher at Indiana University

Publications -  330
Citations -  11498

Yunlong Liu is an academic researcher from Indiana University. The author has contributed to research in topics: Gene & Biology. The author has an hindex of 48, co-authored 275 publications receiving 9310 citations. Previous affiliations of Yunlong Liu include Rutgers University & Harbin Engineering University.

Papers
More filters
Journal ArticleDOI

miR2Disease: a manually curated database for microRNA deregulation in human disease

TL;DR: ‘miR2Disease’, a manually curated database, aims at providing a comprehensive resource of microRNA deregulation in various human diseases by reviewing more than 600 published papers.
Journal ArticleDOI

Predicting intrinsic disorder in proteins: an overview.

TL;DR: In this review of algorithms for intrinsic disorder prediction, the basic concepts of various prediction methods for IDPs are summarized, the strengths and shortcomings of many of the methods are analyzed, and the difficulties and directions of future development of IDP prediction techniques are discussed.
Journal ArticleDOI

Prioritization of disease microRNAs through a human phenome-microRNAome network

TL;DR: A network-based approach that can infer potential microRNA-disease associations and drive testable hypotheses for the experimental efforts to identify the roles of microRNAs in human diseases is presented.
Journal ArticleDOI

Estradiol-regulated microRNAs control estradiol response in breast cancer cells

TL;DR: It is proposed that the clinical course of ERα-positive breast cancers is dependent on the balance between E2-regulated tumor-suppressor micro RNAs and oncogenic microRNAs, and a negative-regulatory loop controlling E2 response through microRN as well as differences in E1-induced transcriptome and proteome.
Journal ArticleDOI

MicroRNA Cluster 221-222 and Estrogen Receptor α Interactions in Breast Cancer

TL;DR: The findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors.